CLNN Clene Inc.

NASDAQ
$3.50

Clene Inc. (CLNN) is expected to report earnings on February 3, 2027, before the market open. The consensus earnings estimate is a loss of $0.50 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -10.9% since its last earnings release on November 4, 2026.

Clene Beat Consensus Estimates
Wednesday, November 4, 2026 · 8:30 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 3
Wednesday · 8:30 AM ET
Earnings Whisper
-
vs ($0.50)
Rev est $90K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.87

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Clene Inc.

Clene, a clinical-stage biopharmaceutical company focused on neurodegenerative disease, is leading the way by using nanotechnology to treat bioenergetic failure, which underlies many neurological diseases.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.